May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Aqueous Humor Concentrations of Growth Factors and Cytokines in Retinal Vein Occlusion and the Effect of Therapy With Bevacizumab
Author Affiliations & Notes
  • M. Funk
    Medical University of Vienna, Vienna, Austria
    Department of Ophthalmology,
  • K. Kriechbaum
    Medical University of Vienna, Vienna, Austria
    Department of Ophthalmology,
  • F. Prager
    Medical University of Vienna, Vienna, Austria
    Department of Ophthalmology,
  • M. Georgopoulos
    Medical University of Vienna, Vienna, Austria
    Department of Ophthalmology,
  • G. Zlabinger
    Medical University of Vienna, Vienna, Austria
    Institute of Immunology,
  • U. Schmidt-Erfurth
    Medical University of Vienna, Vienna, Austria
    Department of Ophthalmology,
  • Footnotes
    Commercial Relationships  M. Funk, None; K. Kriechbaum, None; F. Prager, None; M. Georgopoulos, None; G. Zlabinger, None; U. Schmidt-Erfurth, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4571. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Funk, K. Kriechbaum, F. Prager, M. Georgopoulos, G. Zlabinger, U. Schmidt-Erfurth; Aqueous Humor Concentrations of Growth Factors and Cytokines in Retinal Vein Occlusion and the Effect of Therapy With Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4571. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To identify the impact of antiangiogenic therapy on growth factors and inflammatory cytokines in eyes with branch (BRVO) and central retinal vein occlusion (CRVO).

Methods: : In a prospective clinical trial, 13 eyes of patients with BRVO and CRVO were included. Bevacizumab was administered intravitreously at baseline, month 1 and 2. Re-treatments were given at monthly visits if OCT showed intra- or subretinal fluid, or at vision loss of at least 5 ETDRS letters. Aqueous humor samples were taken each time intravitreal injections were performed. Follow-up was 15 months. Samples from cataract patients served as control.Luminex multiplex assays were used for measurement of 28 growth factors and cytokines.

Results: : Significant differences between patients with BRVO or CRVO and control patients were found in the concentration of IL-1b, IL-5, and Eotaxin. Concentrations of IL-1a, IL-10, IL-15, IL-6, IP-10, MCP-1, PDGF-AA, and VEGF varied between CRVO and control patients.Under anti-VEGF therapy, VEGF levels were significantly reduced. Mean values for BRVO were 125.9pg/ml at baseline, 0.01pg/ml at month 1 (p=0.02), 0.57 pg/ml at month 2 (p=0.01), and 0.68pg/ml at month 3 (p=0.02); for CRVO 904.65pg/ml at baseline, 75.17pg/ml at month 1 (p=0.04), 143.81pg/ml at month 2 (p=0.04), and 129.25pg/ml at month 3 (p=0.07).When criteria for re-treatment were met, VEGF levels were high again (e.g. 53.78 pg/ml in patients with BRVO at month 6; p=0.6). Changes of VEGF levels correlated with visual acuity and central retinal thickness (p<0.001).Other significantly reduced cytokines under therapy were IL-1a, IL-1b, IL-12p40, RANTES, and IP-10 in patients with BRVO, and PDGF-AA, IL-6, IP-10, and MCP-1 in patients with CRVO.

Conclusions: : Intravitreal injections of Bevacizumab resulted in a substantial decrease of VEGF levels. This effect was measurable over a time period of four weeks after injection. VEGF levels remained low under consecutive monthly re-treatment and increased following discontinuation of therapy with recurrent edema.

Clinical Trial: : EudraCT 2006-005684-26

Keywords: aqueous • vascular occlusion/vascular occlusive disease • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×